SCHEMBL4152007

SCHEMBL4152007

N=C(N)Nc1ccc(S(=O)(=O)NCCO)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
CYP2C19 P33261 3/20 0.54
POLB P06746 2/20 0.54
NAMPT P43490 2/20 0.53
GAA P10253 3/20 0.49
PKM P14618 1/20 0.49
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
IKBKB O14920 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
F2 P00734 1/20 0.45
LMNA P02545 2/20 0.44
RAB9A P51151 1/20 0.43
CYP2D6 P10635 2/20 0.43
CYP1A2 P05177 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CYP3A4 P08684 1/20 0.42
SYK P43405 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4158719 0.83 LMNA (0.58) ALDH1A1POLBMEN1KMT2ALMNA
SCHEMBL4161233 0.82 ALDH1A1 (0.61) ALDH1A1POLBNAMPTGAAPKM
SCHEMBL4162355 0.82 CYP2C19 (0.55) ALDH1A1CYP2C19NAMPTGAAPKM
SCHEMBL7621847 0.81 ALDH1A1 (0.75) ALDH1A1CYP2C19POLBNAMPTGAA
SCHEMBL4168948 0.78 KEAP1 (0.61) ALDH1A1CYP2C19NAMPTGAACA1
Nitric Acid SCHEMBL4166300 0.77 ALDH1A1 (0.55) ALDH1A1POLBNAMPTGAAPKM
SCHEMBL12010920 0.77 NAMPT (0.62) ALDH1A1CYP2C19POLBNAMPTGAA
SCHEMBL22619418 0.77 SMN1; SMN2 (0.50) ALDH1A1NAMPTGAACA1CA2
SCHEMBL27718210 0.77 ALDH1A1 (0.60) ALDH1A1CYP2C19POLBNAMPTGAA
SCHEMBL2563975 0.76 CYP3A4 (0.70) ALDH1A1CYP2C19GAAPKMCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed
EP-1756098-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2007-02-28 EP disclosed
WO-2005116025-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CDK2, CDK4, CDK20 ALDH1A1 2743/4885CYP2C19 3067/4885POLB 94/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.